Protective Effects of Estrogen via Nanoparticle Delivery to Attenuate Myelin Loss and Neuronal Death after Spinal Cord Injury

Haque, Azizul; Drasites, Kelsey P; Cox, April; Capone, Mollie; Myatich, Ali I; Shams, Ramsha; Matzelle, Denise; Garner, Dena P.; Bredikhin, Mikhail; Shields, Donald C.; Vertegel, Alexey; Banik, Naren L.

doi:10.1007/s11064-021-03401-2

Cited by 15 publications

(10 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Premarin, a synthetic estrogen used as a hormone replacement therapy (Fugh-Berman, 2010), was also found to improve BBB score after SCI (Chen et al, 2010; Haque et al, 2021). Here, however, it is very important to highlight that one of these studies (Haque et al, 2021) found that low dose Premarin (100µg/kg daily for seven days) caused adverse reactions in their male rats. Specifically, their urine contained a thick, dark blood that was accompanied by pale eyes and lethargy approximately five days into treatment; these adverse events resolved upon the cessation of Premarin therapy (Haque et al, 2021).…”

Section: Resultsmentioning

confidence: 99%

“…Here, however, it is very important to highlight that one of these studies (Haque et al, 2021) found that low dose Premarin (100µg/kg daily for seven days) caused adverse reactions in their male rats. Specifically, their urine contained a thick, dark blood that was accompanied by pale eyes and lethargy approximately five days into treatment; these adverse events resolved upon the cessation of Premarin therapy (Haque et al, 2021). No such side effects were reported for the other study where SCI recovery was also improved but where only a single high dose (1mg/kg) of Premarin was administered (Chen et al, 2010).…”

Section: Resultsmentioning

confidence: 99%

“…In line with this, numerous studies demonstrated that estrogen, Premarin, bazedoxifene, and tamoxifen decreased TUNEL positive staining, a marker of DNA fragmentation during the final stages of apoptosis (Afhami et al, 2016;Chaovipoch et al, 2005;Chen et al, 2010;Haque et al, 2021;Hu et al, 2012;Kachadroka et al, 2010;Kim et al, 2021;Lee et al, 2012;Rong et al, 2012;Samantaray et al, 2010;Samantaray et al, 2011;Sribnick et al, 2006;Tian et al, 2009;Yune et al, 2004;Yune et al, 2008). The beneficial effect of estrogen on decreased TUNEL-positive cells was independent of age, with both two-month and one-year old rats demonstrating estrogen-mediated decreases (Chaovipoch et al, 2005).…”

Section: Estrogen and Estrogenic Compounds Reduce Cell Death Improve ...mentioning

confidence: 85%

“…Several of the included studies examined the effects of estrogen and estrogenic compounds on injury size and other histopathological characteristics after SCI (Table 5). Generally, estrogen, Premarin, and tamoxifen appeared to reduce the lesion size after moderate contusion (via weight drop or impactor) and compression SCI (Chen et al, 2010;Haque et al, 2021;Mosquera et al, 2014;Ni et al, 2018;Ritz & Hausmann, 2008;Yune et al, 2004) and increase the amount of tissue spared (Ni et al, 2018;Samantaray et al, 2016;Sengelaub et al, 2018;Sribnick et al, 2010). Further, estradiol benzoate and bazedoxifene decreased the necrotic tissue area (Kim et al, 2021;Lin et al, 2016) and the phytoestrogen isopsoralen decreased cavitation volume (X. M. .…”

Section: Both Estrogen and Estrogenic Compounds Attenuate The (Histo)...mentioning

confidence: 99%

See 4 more Smart Citations

The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury

Shvetcov

Ruitenberg

Delerue

et al. 2022

Preprint

View full text Add to dashboard Cite

Spinal cord injury (SCI) occurs when the spinal cord is damaged from either a traumatic event or disease. SCI is characterised by multiple injury phases that affect the transmission of sensory and motor signals and lead to temporary or long-term functional deficits. There are few treatments for SCI. Estrogens and estrogenic compounds, however, may effectively mitigate the effects of SCI and therefore represent viable treatment options. This review systematically examines the pre-clinical literature on estrogen and estrogenic compound neuroprotection after SCI. Several estrogens were examined by the included studies: estrogen, estradiol benzoate, Premarin, isopsoralen, genistein, and selective estrogen receptor modulators. Across these pharmacotherapies, we find significant evidence that estrogens indeed offer protection against myriad pathophysiological effects of SCI and lead to improvements in functional outcomes, including locomotion. A STRING functional network analysis of proteins modulated by estrogen after SCI demonstrated that estrogen simultaneously upregulates known neuroprotective pathways, such as HIF-1, and downregulates pro-inflammatory pathways, including IL-17. These findings highlight the strong therapeutic potential of estrogen and estrogenic compounds after SCI.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Estrogen and Estrogenic Compounds Reduce Cell Death Improve ...mentioning

confidence: 85%

Section: Both Estrogen and Estrogenic Compounds Attenuate The (Histo)...mentioning

confidence: 99%

See 3 more Smart Citations

The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury

Shvetcov

Ruitenberg

Delerue

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Nanotherapeutics for Alleviating Anesthesia‐Associated Complications

Lu,

Wei,

Shi

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Current management of anesthesia‐associated complications falls short in terms of both efficacy and safety. Nanomaterials with versatile properties and unique nano‐bio interactions hold substantial promise as therapeutics for addressing these complications. This review conducts a thorough examination of the existing nanotherapeutics and highlights the strategies for developing prospective nanomedicines to mitigate anesthetics‐related toxicity. Initially, general, regional, and local anesthesia along with the commonly used anesthetics and related prevalent side effects are introduced. Furthermore, employing nanotechnology to prevent and alleviate the complications of anesthetics is systematically demonstrated from three aspects, that is, developing 1) safe nano‐formulization for anesthetics; 2) nano‐antidotes to sequester overdosed anesthetics and alter their pharmacokinetics; 3) nanomedicines with pharmacodynamic activities to treat anesthetics toxicity. Finally, the prospects and challenges facing the clinical translation of nanotherapeutics for anesthesia‐related complications are discussed. This work provides a comprehensive roadmap for developing effective nanotherapeutics to prevent and mitigate anesthesia‐associated toxicity, which can potentially revolutionize the management of anesthesia complications.

show abstract

Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases

Keshavarz Shahbaz,

Koushki,

Keshavarz Hedayati

et al. 2024

Medicinal Research Reviews

View full text Add to dashboard Cite

Nanoparticles (NPs) that target multiple transport mechanisms facilitate targeted delivery of active therapeutic agents to the central nervous system (CNS) and improve therapeutic transport and efficacy across the blood‐brain barrier (BBB). CNS nanotherapeutics mostly target neurons and endothelial cells, however, microglial immune cells are the first line of defense against neuronal damage and brain infections. Through triggering release of inflammatory cytokines, chemokines and proteases, microglia can however precipitate neurological damage—a significant factor in neurodegenerative diseases. Thus, microglial inhibitory agents are attracting much attention among those researching and developing novel treatments for neurodegenerative disorders. The most established inhibitors of microglia investigated to date are resveratrol, curcumin, quercetin, and minocycline. Thus, there is great interest in developing novel agents that can bypass or easily cross the BBB. One such approach is the use of modified‐nanocarriers as, or for, delivery of, therapeutic agents to the brain and wider CNS. For microglial inhibition, polymeric NPs are the preferred vehicles for choice. Here, we summarize the immunologic and neuroinflammatory role of microglia, established microglia inhibitor agents, challenges of CNS drug delivery, and the nanotherapeutics explored for microglia inhibition to date. We also discuss applications of the currently considered “most useful” polymeric NPs for microglial‐inhibitor drug delivery in CNS‐related diseases.

show abstract

Protective Effects of Estrogen via Nanoparticle Delivery to Attenuate Myelin Loss and Neuronal Death after Spinal Cord Injury

Cited by 15 publications

References 88 publications

The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury

The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury

Nanotherapeutics for Alleviating Anesthesia‐Associated Complications

Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases

Contact Info

Product

Resources

About

Protective Effects of Estrogen via Nanoparticle Delivery to Attenuate Myelin Loss and Neuronal Death after Spinal Cord Injury

Cited by 15 publications

References 88 publications

The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury

The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury

Nanotherapeutics for Alleviating Anesthesia‐Associated Complications

Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases

Contact Info

Product

Resources

About

Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases